Century Therapeutics Shareholders Approve 50% Increase in Authorized Common Stock

summarizeSummary

Century Therapeutics shareholders approved a charter amendment to increase authorized common stock by 150 million shares, providing significant capacity for future capital raises but also substantial potential dilution.

check_boxKey Events

• Shareholder Approval for Authorized Stock Increase

  Shareholders approved an amendment to increase authorized common stock from 300 million to 450 million shares, as proposed in prior proxy filings.

• Charter Amendment Becomes Effective

  The amendment to the Certificate of Incorporation was filed on June 11, 2026, and became effective on June 12, 2026.

• Significant Potential Dilution Created

  The increase creates headroom for issuing an additional 269.6 million shares. If all authorized shares were issued, dilution would be approximately 149.5% based on the 180.3 million shares outstanding as of the record date.

• Routine Annual Meeting Matters Approved

  Shareholders also approved the election of two Class II directors and ratified Ernst & Young LLP as the independent registered public accounting firm for 2026.

auto_awesomeAnalysis

Shareholders have approved an amendment to the company's charter, increasing the authorized common stock from 300 million to 450 million shares. This authorization, which became effective today, significantly expands the company's capacity to issue new shares. With approximately 180 million shares currently outstanding, this move creates headroom for potential future capital raises, but also introduces substantial potential dilution for existing shareholders if the company utilizes the full authorization. This follows recent capital raising activities, including a private placement and an active at-the-market (ATM) program.